Market Publishers Ltd and ProGrow Pharma Partners Sign Partnership Agreement11 Sep 2017 • by Natalie Aster
LONDON – Market Publishers Ltd and ProGrow Pharma (PGP) Partners signed a partnership agreement for quality market research promotion on Internet. MarketPublishers.com is now authorised to distribute and sell research reports created by PGP Partners.
Natalie Aster, Assistant Manager at Partners Department, commented on the agreement as follows: “We are extremely happy to have in our team a new member from India – PGP Partners. For more than 10 years, this advisory company has been focusing exclusively on research into the pharmaceutical and biotech industry, catering the full scope of services for the healthcare companies and its investors. Its team of devoted professionals has a profound understanding of the medical science and challenges related to innovation, development of drugs, patents and litigations, clinical research, competition across various geographies, and the competitive scene in the given therapy, among others. With its in-depth domain competence and awareness of the intricacy of the industry dynamics, PGP Partners supports its clients in taking strategic decisions to boost the growth of their businesses.” Natalie added: “We believe that our collaboration with PGP Partners will not only bear fruit for both parties but also serve the interests of our numerous customers the world over.”
Insightful market research publication by PGP Partners:
Poly(adenosine diphosphate [ADP]–ribose) Polymerases (PARPs) Inhibitors Successful targeting of DNA Repair Pathways by PARP Inhibitors – Current and Future Potential. During the past 4 years 3 drugs targeting PARPs got FDA approval to treat ovarian cancer (OC) (BRCA mutant) and novel clinical findings support onward label expansion of this drug class in other solid tumours. PARP inhibitors have exhibited apparent patient benefit in germline BRCA (gBRCA), HR-deficient, and other OC types. There is a big market opportunity for this drug class in the approved OC indication, with the best is drawing near from the label expansion for other cancer types as a single agent therapy or together with other targeted medications. The market opportunity of this drug class has been estimated at beyond USD 5 billion, which will likely boost M&A activity of innovative firms under lucrative terms for them. The report sheds lights on the rationale of inhibiting PARP in various cancers and the clinical findings that have a promising future. Clinical progress of PARP inhibitors as a single agent therapy against tumours with current DNA repair defects, like BRCA1 and BRCA2 and other mutations, and as a combined treatment when provided with other targeted therapies along with chemotherapeutic agents that inflict DNA damage. More information is at hand in the research ...
More details on the publisher and its reports can be found at PGP Partners page.